Date Time
Australian drug discovery to be studied in US
A drug candidate discovered by the Australian company Pharmaxis (ASX:PXS) will be the focus of a new trial aimed at studying its potential as a treatment for an aggressive and deadly form of brain cancer.
The trial, which is being funded through a grant from the Charlie Teo Foundation, will enter pre‐clinical efficacy testing for glioblastoma (GBM). GBM is the most common form of brain cancer with an average survival of only 15 months from diagnosis.
The grant of $186,837 will go towards the study of PXS‐5505 at The University of Texas MD Anderson Cancer Center. The drug is a potent inhibitor of lysyl oxidase that is thought to play a crucial role in GBM because they attract inflammatory cells that accelerate tumour growth and reduce survival.